2017年我們?cè)趪?guó)際雜志Current neuroppharmacology發(fā)表了一篇綜述文章，概述了在缺血性中風(fēng)治療中，延遲使用溶栓劑rt-PA引出出血轉(zhuǎn)換的細(xì)胞分子機(jī)制，以及目前中藥單體治療中風(fēng)的靶點(diǎn)。title:
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
文章中羅列了23個(gè)能夠同時(shí)作用于多個(gè)靶點(diǎn)的中藥單體，并對(duì)靶點(diǎn)進(jìn)行了分析歸納總結(jié)，并對(duì)這些單體和t-PA聯(lián)用的可能性進(jìn)行分析。最后，我們提出了在中藥單體研究以及中藥單體和t-PA聯(lián)用的研究中需要注意的事項(xiàng)，包括藥物使用劑量，藥物作用時(shí)間窗；藥物長(zhǎng)期效果評(píng)價(jià)；評(píng)價(jià)指標(biāo)；以及藥物相互作用等。
23個(gè)單體包括:和厚樸酚 (Honokiol);；）（Huperzine A；石杉?jí)A甲- A）（Tanshinone IIA,丹參酮IIA）baicalin（：黃芩苷
葛根素?Puerarin；仙茅?Curculigoside ?；紫草素?Shikonin； 甘草酸?Glycyrrhizin ?；天麻素?Gastrodin；人參皂苷Rg1 ?Ginsenoside Rg1 ?；丹皮酚?Paeonol ；夾竹桃麻素?Apocynin ?；黃芪甲苷IV ??Astragaloside IV；?蛇床子素?Osthole ；咖啡酸Caffeic acid；厚樸酚?Magnolol； 粉防己堿?Tetrandrine； 芍藥苷?Paeoniflorin；?燈盞花素?Scutellarin ；水飛薊素Silymarin ；小檗堿?Berberine；?阿魏酸?Ferulic acid； 川芎嗪?Tetramethylpyrazine
作用靶點(diǎn)包括；；Reactive Nitrogen Species (RNS) and Reactive Oxygen Species (ROS)；Activated Protein C (APC)；N-methyl-D-aspartic Receptor (NMDAR)；Platelet-derived Growth Factor-CC (PDGF-CC)；Vascular Endothelial Growth Factor (VEGF)；High Mobility Group Box Protein 1 (HMGB1)；Matrix metalloproteinase-9 (MMP-9)；?NF-κB：Low-density Lipoprotein Receptor-related Protein 1 (LRP-1)
英文摘要：
Abstract: Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic
molecularbioactivitiessimultaneously targeting several importantcurrently available literature with theneurotoxicityin ischemic brain injury. Based on these targets, we select 23 promising compounds fromcurrent progress about molecular targets involving in t-PA-mediated HT and)-protective effects by concurrently targeting multiple cellular signaling pathways in cerebral ischemia-reperfusion injury. Thus, those compounds are potential to be one-drug-multi-target agents as combined therapy with t-PA for ischemic stroke. In this review article, we summarizeneuro- and blood-brain-barrier (BBBneurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time window. However, therapies modulating single target seem not to be satisfied, and a multi-target strategy is warranted to resolve such complex disease. Recently, large amount of efforts have been made to explore the active compounds from herbal supplements to treat ischemic stroke. Some natural compounds revealed bothtransformation (HT) and
targets. We propose that those compounds merit further investigation as combined therapy with t-PA. Finally, we discuss the potential drawbacks of the natural compounds' studies and raise several important issues to be addressed in the future for the development of natural compound as an adjunct therapy.
Keywords: Combination therapy, hemorrhagic transformation, ischemic stroke, multi-target, natural compounds,neurotoxicity, tissue plasminogen activator (t-PA).
文獻(xiàn)：
Chen H-S, Qi S-H, Shen J-G. One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.Current Neuropharmacology. 2017;15(1):134-156.:10.2174/1570159X14666160620102055.doi
